文献速递消化内镜

随机临床试验:粪便微生物群移植治疗复发性艰难梭菌感染——经结肠镜给予来自少量健康供体的新鲜、冷冻或冻干微生物群

Randomised clinical trial: faecal microbiota transplantation for recurrent Clostridum difficile infection - fresh, or frozen, or lyophilised microbiota from a small pool of healthy donors delivered by colonoscopy.
PubMed 文献 · Aliment Pharmacol Ther · 2017-02-21

72例复发性艰难梭菌感染受试者随机双盲接受经结肠镜给予的新鲜、冷冻或冻干粪便微生物群移植产品,随访2个月总体缓解率87%;新鲜产品治愈率25/25(100%)最高,冻干产品16/23(78%)最低,冷冻产品20/24居中;新鲜或冷冻产品组微生物多样性第7天重建,冻干组第30天重建。

要点

  • 新鲜产品治愈率25/25(100%),冻干产品16/23(78%),冷冻产品20/24。
  • 冻干产品与新鲜产品比较P=0.022,与冷冻产品比较P=0.255。
  • 新鲜或冷冻产品组微生物多样性第7天重建,冻干组第30天重建。

核心结论

  • 来自同一供体的新鲜或冷冻粪便产品在粪便微生物群移植中观察到相当的疗效。
  • 冻干产品疗效较新鲜产品略低,但粪便微生物群移植后1个月时微生物恢复与其他治疗相似。

研究设计与样本

  • 双盲随机临床试验,纳入72例有≥3次艰难梭菌感染发作的受试者。
  • 受试者随机接受经结肠镜给予的新鲜、冷冻或冻干粪便微生物群移植产品,每次治疗使用来自8名健康供体的50 g粪便。

主要发现

  • 粪便微生物群移植后2个月随访期间艰难梭菌感染总体缓解率为87%。
  • 新鲜产品组治愈25/25(100%),冻干产品组16/23(78%;与新鲜产品比较P=0.022,与冷冻产品比较P=0.255),冷冻产品组20/24(与新鲜产品比较P=0.233)。
  • 粪便微生物群移植前粪便样本细菌多样性显著降低,变形菌门比例高。
  • 接受新鲜或冷冻产品的受试者微生物多样性在第7天重建。
  • 随机接受冻干材料的受试者多样性在第7天改善,第30天重建。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Faecal microbiota transplantation (FMT) has become routine in managing recurrent C. difficile infection (CDI) refractory to antibiotics. AIM: To compare clinical response and improvements in colonic microbiota diversity in subjects with recurrent CDI using different donor product. METHODS: Seventy-two subjects with ≥3 bouts of CDI were randomised in a double-blind study to receive fresh, frozen or lyophilised FMT product via colonoscopy from 50 g of stool per treatment from eight healthy donors. Recipients provided stools pre- and 7, 14 and 30 days post-FMT for C. difficile toxin and, in a subset, microbiome composition by 16S rRNA gene profiling. RESULTS: Overall resolution of CDI was 87% during 2 months of follow-up after FMT. Stool samples before FMT had significantly decreased bacterial diversity with a high proportion of Proteobacteria compared to donors. Cure rates were highest for the group receiving fresh product seen in 25/25 (100%), lowest for the lyophilised product 16/23 (78%; P = 0.022 vs. fresh and 0.255 vs. frozen) and intermediate for frozen product 20/24 (P = 0.233 vs. fresh). Microbial diversity was reconstituted by day 7 in the subjects receiving fresh or frozen product. Improvement in diversity was seen by day 7 in those randomised to lyophilised material with reconstitution by 30 days. CONCLUSIONS: Comparative efficacy in faecal microbiota transplantation was observed in subjects receiving fresh or frozen faecal product from the same donors. The lyophilised product had a slightly lowered efficacy compared with fresh product, but it resembled other treatments in microbial restoration 1 month after faecal microbiota transplantation.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Jiang ZD, Ajami NJ, Petrosino JF, et al. Randomised clinical trial: faecal microbiota transplantation for recurrent Clostridum difficile infection - fresh, or frozen, or lyophilised microbiota from a small pool of healthy donors delivered by colonoscopy. Aliment Pharmacol Ther. 2017. PMID: 28220514. doi:10.1111/apt.13969

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。